NEXI

NexImmune, Inc.

6.84 USD
+0.06 (+0.88%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

NexImmune, Inc. stock is down -53.56% since 30 days ago. The next earnings date is Mar 26, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 3 February’s closed higher than January.

About NexImmune, Inc.

NexImmune, Inc. engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials.